Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
Open Access
- 1 September 2015
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 23 (9), 1456-1464
- https://doi.org/10.1038/mt.2015.103
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarctionNature Biotechnology, 2013
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisThe New England Journal of Medicine, 2013
- Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi TherapeuticsMolecular Therapy, 2013
- Modified Foxp3 mRNA protects against asthma through an IL-10–dependent mechanismJCI Insight, 2013
- Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionNature Biotechnology, 2012
- Developing mRNA-vaccine technologiesRNA Biology, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie, 2012
- Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding ErythropoietinMolecular Therapy, 2012
- Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase LNucleic Acids Research, 2011
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011